ERBB2 and breast carcinoma: Two retrospective studies evaluating response of DCIS adjacent to HER2-positive breast cancer found that 36–51% of these DCIS lesions were eradicated after trastuzumab-containing NST combined with pertuzumab in a small subgroup [24, 25].